focus -WSS

focus

author：hotspot 2025-09-05 11:24:59 - browse：24

Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Bernie Sanders gets little from pharma CEOs on drug prices

hotspot

WSS

Study gives hint on South Asians’ higher risk of cardiovascular disease

Menendez indictment could see pharma lose a key ally

Would Medicare drug price negotiations stall in a shutdown?

Sudafed saga points to U.S. issues with evaluating older drugs

Abbott's new heart device gets FDA advisory panel nod

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

focus

focus

Duchenne breakthrough therapy leaves behind pioneering families

Congress might make insulin pumps more accessible to the blind

Cancer drug shortages should be causing more outrage

Congress might make insulin pumps more accessible to the blind

How one medical school became remarkably diverse

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Cancer drug shortages should be causing more outrage

Artificial intelligence use in health care faces greater scrutiny in 2024

Cancer drug shortages should be causing more outrage

Juul documents reveal insider tactics on political lobbying

hotspot

Medicare drug price negotiation program allowed for now

Sudafed saga points to U.S. issues with evaluating older drugs

Congress must protect the remaining independent doctors

Medicaid, Medicare dual

Researchers use wearables data and AI to predict preterm birth risk

Artificial intelligence use in health care faces greater scrutiny in 2024

explore

Wikipedia

hotspot

entertainment